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Abstract
Background: Ciliated muconodular papillary tumors (CMPTs) are newly recognized rare peripheral lung nodules
that are histologically characterized by ciliated columnar, goblet, and basal cells. Although recent studies have
shown that CMPTs constitute a neoplastic disease, the complete histogenesis of CMPTs is not fully understood and
molecular data are limited.
Methods: We reviewed four cases of CMPT and performed immunohistochemical and genomic analyses to
establish CMPT profiles.
Results: All cases were positive for hepatocyte nuclear factor-4α and mucin 5B and negative for programmed
death ligand 1 expression, as determined by immunohistochemistry. The genetic analysis revealed three
pathogenic mutations (BRAF V600E, AKT1 E17K, and KRAS G12D), with the KRAS mutation reported here for the first
time.
Conclusion: Histological and genetic profiles indicate that CMPTs are likely neoplastic and exhibit features similar
to mucinous adenocarcinoma. This suggests that some CMPTs may be a precursor lesion of mucinous
adenocarcinoma.
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Background
Ciliated muconodular papillary tumors (CMPTs) are a
newly recognized small-size papillary tumor of the per-
ipheral lung that contain columnar cells, occasional
basal cells, and mucus-producing cells as well as extra-
cellular mucin pools of various sizes. Although CMPTs
were first described based on certain pathological fea-
tures that suggested a malignant potential, similar dis-
eases such as extremely well-differentiated papillary
adenocarcinoma with prominent cilia formation have
been reported under different names [1–3]. Due to its
complex histology and presence of inflammation and fi-
brosis, the metaplastic nature of CMPTs has been de-
bated. However, recent reports have revealed the
frequent presence of driver gene mutations, and CMPT
is now recognized as a neoplasia [4–6]. The histogenesis
and molecular characteristics of CMPTs are not well
understood owing to the rarity of the disease. To address
this issue, we reviewed our case archive and character-
ized CMPTs by immunohistochemistry and next-
generation sequencing (NGS).
Methods
Patient selection and tissue preparation
Cases of surgically resected CMPT from 2012 and 2016
were searched in the pathology archive of Nagasaki Uni-
versity Hospital. Hematoxylin and eosin-stained slides of
each case were reviewed by two pathologists specializing
in thoracic medicine. We identified four CMPT cases;
two of these had been originally diagnosed as CMPT,
whereas the other cases had been diagnosed as glandular
papilloma and mucinous adenocarcinoma. Clinical data
were extracted from the hospital’s electronic medical re-
cords. Sections with a thickness of 4 μm from formalin-
fixed, paraffin-embedded (FFPE) tissue samples were ex-
amined by immunohistochemistry, and 15 sections with
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a thickness of 5 μm were subjected to NGS of 50
cancer-related genes using the Ion Torrent PGM sys-
tem (Life Technologies, Carlsbad, CA), and10 μm
thick section on the conventional glass slide were
submitted for 29 genes analysis using MiSeq (Illu-
mina, San Diego, CA, USA).
Isolation of genomic DNA
Genomic DNA was extracted from FFPE tumor samples
using the QIAamp DNA FFPE kit (Qiagen, Valencia,
CA, USA), and the concentration was determined using
the Quant-iT PicoGreen dsDNA Assay kit (Life
Technologies).
Targeted deep sequencing of mutational hotspots in 50
cancer-related genes
Genomic DNA was subjected to whole-exome sequen-
cing using the Ion AmpliSeq Cancer Hotspot Panel v.2
(Life Technologies) according to the manufacturer’s in-
structions. The purified library was sequenced on an Ion
PGM instrument using Ion PGM Hi-Q Sequencing kit
and Ion 318 Chip Kit v.2 (all from Life Technologies).
DNA sequencing data were accessed with the Torrent
Suite v.5.0 program (Life Technologies). The coverage
analysis was performed using the coverage analysis plug-
in v5.0. Reads were aligned with the hg19 human refer-
ence genome, and potential mutations were identified
using Variant Call Format v.5.0. Raw variant calls were
annotated with CLC Genomics Workbench software
(CLC bio, Aarhus, Denmark). Variants were manually veri-
fied using the integrative genomics viewer (Broad Institute,
Cambridge, MA, USA). Known single nucleotide polymor-
phisms were identified using the Human Genetic Variation
Database (http://www.hgvd.genome.med.kyoto-u.ac.jp/)
[7] and were excluded.
We also performed sequencing on Illumina MiSeq in-
strument. As recommended by the manufacturer, 50 ng
of dsDNA was used for generating sequencing libraries
using Find-It cancer hotspot panel (Contextual Genom-
ics, Vancouver, BC, Canada). The panel targets 90+ can-
cer hotspot mutations including eight coding exons in
29 cancer-related genes. DNA libraries were denatured
and diluted as per Illumina’s recommendations. Samples
were run on MiSeq machine using 300 cycle MiSeq Re-
agent Kit V2 (Cat.No.MS-102-2002, Illumina).
Immunohistochemistry
Immunohistochemical analysis of 4-μm tissue sections
was carried out using the Ventana Bench Mark XT Au-
tomated stainer (Ventana Medical Systems, Tucson, AZ,
USA) and BOND III fully automated stainer (Leica Bio-
systems, Melbourne, Australia) with antibodies against
thyroid transcription factor (TTF)-1 (clone SPT24; Leica
Novocastra, Newcastle Upon Tyne, UK), hepatocyte
nuclear factor (HNF)-4α (clone H1415; Perseus Proteo-
mics, Tokyo, Japan), mucin (MUC)5B (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), MUC5A (clone
CLH2; Leica Novocastra), cytokeratin (CK)7 (clone OV-
TL12/30; Dako Japan, Tokyo, Japan), CK20 (clone
Ks20.8; Dako Japan), p53 (clone DO-7; Leica Novocas-
tra), Ki-67 (clone MIB-1; Dako Japan), Caudal-type
homeobox (CDX)2 (clone EPR2764Y; Roche Diagnostics,
Indianapolis, IN, USA), ALK (clone D5F3; Roche Diag-
nostics), BRAF V600E (clone VE1; Roche Diagnostics)
and programmed death ligand (PD-L)1 (clone SP142;
Spring Bioscience, Pleasanton, CA, USA). Details of op-
timized staining protocols are listed in Additional file 1.
HNF4α, MUC5B, MUC5A, CK7, and CK20 staining was
scored as follows: −, negative; 1+, focal; and 2+, diffuse.
The intensity of p53 expression was assessed as follows:
1+, faint and sporadic; 2+, frequently positive with no or
equivocal overexpression; and 3+, unequivocal and dif-
fuse overexpression. BRAF V600E and ALK expression
was judged as positive when strong and diffuse staining
was observed in cancer cells. The percentage of Ki-67-
immunopositive cells was analyzed using a nuclear algo-
rithm (Nuclear_v.9_v.10.0.0.1798; Imagescope, Leica Bio-
systems, Nussloch, Germany). PD-L1 expression was
scored as the percentage of PD-L1-positive cells among
tumor cells. CDX2 expression was scored as follows: −,
negative; 1+, ≤ 25% positive; 2+, > 25 and <50% positive;
and 3+, ≥ 50% positive. Two observers (E.U. and J.F.) in-
dependently scored the staining and a consensus was ob-
tained through discussion when there was a discrepancy.
Results
Clinical summary
Clinical data for the four CMPT patients are summa-
rized in Table 1. The patients were all female with a me-
dian age of 67 years old. None had a history of smoking.
Tumors ranged in size from 8 to 25 mm (median:
11 mm). Lobectomy was performed in three cases, and
segmentectomy was carried out in one case.
Histological findings
The histological features of the four CMPT cases were
consistent with those previously reported [1, 8, 9]. That
is, the tumors typically exhibited a mixture of acinar and
papillary growth patterns without clear evidence of inva-
sion, and were surrounded by abundant mucus pools in
the alveolar spaces (Fig. 1a). The tumors were composed
of two basal cell layers and surface epithelia. The latter
consisted of an uneven mosaic of ciliated columnar, gob-
let, and mucin-producing epithelial cells of the gastric
type (Fig. 1b). Few tumor cells showed nuclear atypia,
and no mitosis or necrosis was observed.
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Driver Mutation Other Mutations NGS panel
Kamata et al.
[4]
62 7/3 5/5 BRAF V600E, 4 cases;
EGFR ex19del E746-T751,
3 cases; BRAF G606R, 1 case
IDH1 G123R, 1 case; CTNNB1 D32N,
1 case; PTPN11 E76K, 1 case;
PTPN11 P491L, 1 case;
TP53 L289F, 1 case
Ion AmpliSeq Cancer
Hotspot Panel v2
Liu et al. [5] – 1/3 – BRAF V600E, 1 case AKT1 E17K, 1 case Ion AmpliSeq Cancer
Hotspot Panel v2
Lau et al. [15] 19 0/1 0/1 none none Ion Ampliseq Colon and
lung cancer panel
Our series 67 0/4 0/4 BRAF V600E 1 case
KRAS G12D, 1 case
AKT1 E17K, 1 case Ion AmpliSeq Cancer
Hotspot Panel v2; The Contextual
Genomics Find-ItTM test
F female, M male
Fig. 1 Immunohistochemical analysis of CMPTs. a Low magnification view of a CMPT showing papillary epithelial proliferation with abundant mucus
production. b Higher magnification view of the same case showing a mixture of goblet, ciliated columnar, and basal cells (arrow). c HNF-4α positivity
in epithelial cell nuclei. Scale bar = 60 μm. d The positive rate for Ki-67 expression was <10%. Scale bar = 100 μm. e Focal MUC5AC staining in
occasional ciliated cells. Scale bar = 90 μm. f Epithelial cells and mucin were strongly positive for MUC5B. Scale bar = 2 mm. g BRAF V600E staining
was strong and diffuse in most epithelial cells of a case harboring BRAF V600E and AKT1 E17K mutations. Scale bar = 60 μm. h PD-L1 staining was
mostly negative (< 1%); however, focal membranous immunoreactivity was observed. Scale bar = 70 μm
Udo et al. Diagnostic Pathology  (2017) 12:62 Page 3 of 5
Immunohistochemistry
All four cases were positive for nuclear HNF4α and
TTF-1. Two cases showed diffuse and strong staining
for HNF4α, as seen in mucinous adenocarcinoma or
colorectal carcinoma (Fig. 1c). The Ki-67 index was low
(2.5%–10%), consistent with a less aggressive nature (Fig.
1d). In contrast to mucinous adenocarcinoma, all cases
examined in this study showed diffuse TTF-1 positivity
and one case showed possible overexpression. There was
sparse cytoplasmic expression of MUC5AC (Fig. 1e)
while diffuse MUC5B—which is very rare in the normal
lung parenchyma—was detected in all cases (Fig. 1f ).
Nuclear expression of p53 was sporadic in one case and
more frequent in two cases, and in one case p53 was
clearly overexpressed. There were no or only a few cells
that were positive for CDX2 and CK20. p63 expression
highlighted the basal layers in all cases, although the
area of coverage was focal in two cases and broad in the
two others (Table 2).
One case with BRAF V600E mutation identified by NGS
showed diffuse and strong BRAF V600E staining, while the
other three cases showed none (Fig. 1g). There was no ALK
and EGFR mutations identified in our cases. ALK status
was also confirmed by immunohistochemistry.
All cases exhibited <1% PD-L1 positivity in tumor cell
membranes (Fig. 1h). These findings suggest that CMPTs
are tumors that originated from a terminal respiratory
unit and are showed features of gastric-type glands.
Genetic analysis
Gene mutations were detected in two of the four cases
(50%) (Table 1). One case harbored BRAF V600E and
AKT1 E17K mutations—which was interestingly identi-
cal as what have been recently reported [4, 5]—and an-
other had a KRAS G12D mutation. The detected
mutation status was identical on both Ion PGM instru-
ment system and Illumina MiSeq system. A KRAS G12C
mutation was found in one of the two other cases; how-
ever, the significance of this mutation is unclear due to
its low frequency.
Discussion
We carried out immunohistochemical and molecular
analyses of four cases of CMPT and identified a previ-
ously unreported KRAS mutation in addition to known
BRAF and AKT1 mutations. The findings of BRAF and
AKT1 mutations were identical to those reported in re-
cent studies [4, 5]. However, we could not identify either
EGFR or ALK mutation in our cases [4, 6, 10].
Interestingly, the case with a KRAS G12D mutation
detected by Ion PGM and Illumina method showed
fewer basal cell layers, as confirmed by p63 immuno-
staining, while another case with reduced basal cell layer
coverage also had a KRAS mutation (G12C). We did not
take this mutation into account due to its low frequency
by Ion PGM method and negative result by Illumina
method. This KRAS status could be due to intratumoral
heterogeneity—i.e., the few cells harboring this mutation
may have been overshadowed by wild-type cells, which
constituted the majority of the tumor cells.
Our immunostaining results were consistent with
previous reports [6, 8, 10–16]. However, we showed
for the first time that CMPTs were positive for HNF-
4α and MUC5B. Although these tumors show similar-
ities to mucinous adenocarcinoma, there are signifi-
cant differences between them such as the presence
of cilia in columnar epithelia and basal cell interven-
tion in the latter. In addition, invasive mucinous
adenocarcinoma is usually TTF-1-negative and has
distinct malignant features [17].
Conclusion
This is the first report of CMPTs of the lung harboring a
KRAS mutation. Our findings suggest that CMPT cases
Table 2 Summary of immnohistochemical findings in previouse reports and present cases
Author TTF-1 Ki67 CK7 CK20 MUC5AC MUC5B p53 HNF4α p63/p40 CDX2 PD-L1 ALK BRAF V600E
Sato et al. [8] 2/2 3%; 10% 2/2 0/2 1/2 - - - - - - - -
Chuang et al. [14] 1/1 <1% 1/1 0/1 - - 0/1 - 1/1 - - - -
Chu et al. [13] 1/1 - 1/1 0/1 - - - - 1/1 - - - -
Kon et al. [12] 5/5 <1%; 5 5/5 0/5 0/5 - 0/5 - 5/5 - - - -
Lau et al. [15] 1/1 not increase 1/1 0/1 1/1(weak) - - - 1/1 - - - -
Kamata et al. [4, 11] +a - - - +a
(cliated cells)
- - 0/10a +a - - - 4/4b
Ishikawa et al. [16] 3/5 <5% 3; <10% 1 5/5 0/5 - - 3/3 - - - - - -
Taguchi et al. [10] 0/1 3.7% 1/1 0/1 1/1 - <1% - 1/1 - - 1/1 0/1
Jin et al. [6] 1/1 - 1/1 - - - - - 1/1 - - 1/1 -
Our series 4/4 <5% 3; <10% 1 4/4 0/4 4/4 4/4 1/4 4/4 4/4d 0/4 <1% 4/4 0/4 1/4c
-; not available, anumbers of positive/negative not reported, bcases with BRAF mutation, ccase with BRAF mutation was positive (1/1), done case was a few as
positive
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are heterogeneous, and some CMPT cases may be a pre-
cancerous form of invasive mucinous adenocarcinoma,
although additional studies are needed to investigate this
possibility.
Additional file
Additional file 1: Antibodies used for immunohistochemistry. (XLSX 10 kb)
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